How the big pharma companies are performing
01) Up 27.2%. LLY (#03 in 2011, #05 in 2010)
02) Up 25.0%. MRK (#08 in 2011, #03 in 2010)
03) Up 21.9%. SNY (#06 in 2011, #10 in 2010)
04) Up 19.1%. PFE (#02 in 2011, #06 in 2010)
05) Up 17.7%. ABT (#04 in 2011, #09 in 2010)
06) Up 10.4%. NVS (#10 in 2011, #01 in 2010)
07) Up 09.5%. JNJ (#07 in 2011, #07 in 2010)
08) Up 00.7%. AZN (#09 in 2011, #04 in 2010)
09) Dn 00.7%. GSK (#05 in 2011, #08 in 2010)
10) Dn 04.2%. BMY (#01 in 2011, #02 in 2010)
Up 12.6%. Avg. of the ten big pharmas
Up 11.9%. Avg. of PFE's nine big peers
Up 15.7%. Avg. of the six domestic pharmas
Up 15.0%. Avg. of PFE's five domestic peers
Up 08.1%. Avg. of the four European pharmas
Up 13.9%. S & P 500 (1,258 to 1,433)
Note: This is the first time in the five years I've been keeping track where LLY has topped a list.
Note: ABT had been the chart-topper for nine consecutive weeks before tumbling to #5 this week.
Note: This is the first time in 2012 when the average of the domestic pharmas has topped the S & P 500.
Note: This is the widest differential of the year between the domestic and European big pharma averages..
Sentiment: Buy